Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Operating Leases (2019 - 2023)

Historic Operating Leases for Spyre Therapeutics (SYRE) over the last 5 years, with Q1 2023 value amounting to $3.8 million.

  • Spyre Therapeutics' Operating Leases fell 1441.68% to $3.8 million in Q1 2023 from the same period last year, while for Mar 2023 it was $3.8 million, marking a year-over-year decrease of 1441.68%. This contributed to the annual value of $4.0 million for FY2022, which is 1310.76% down from last year.
  • Spyre Therapeutics' Operating Leases amounted to $3.8 million in Q1 2023, which was down 1441.68% from $4.0 million recorded in Q4 2022.
  • In the past 5 years, Spyre Therapeutics' Operating Leases ranged from a high of $5.1 million in Q4 2020 and a low of $372000.0 during Q1 2019
  • In the last 5 years, Spyre Therapeutics' Operating Leases had a median value of $4.7 million in 2019 and averaged $4.4 million.
  • In the last 5 years, Spyre Therapeutics' Operating Leases skyrocketed by 119435.48% in 2020 and then tumbled by 1441.68% in 2023.
  • Over the past 5 years, Spyre Therapeutics' Operating Leases (Quarter) stood at $4.7 million in 2019, then increased by 8.85% to $5.1 million in 2020, then fell by 10.16% to $4.6 million in 2021, then decreased by 13.11% to $4.0 million in 2022, then fell by 4.52% to $3.8 million in 2023.
  • Its Operating Leases was $3.8 million in Q1 2023, compared to $4.0 million in Q4 2022 and $4.2 million in Q3 2022.